Invest1 publisher2 min readPublished
Aimed Bio targets 15 clinical trials by 2030, holds 84.2 billion won in available assets
Aimed Bio is adding antibody-oligonucleotide conjugates and brain disease to a pipeline built on ADCs, and it is paying for the expansion out of milestone payments triggered by other companies' trials.
The Investor · Invest desk
What happened
- Aimed Bio said it will extend its antibody-drug conjugate work into antibody-oligonucleotide conjugates and beyond cancer into central nervous system disease, starting with a blood-brain barrier shuttle platform.
- Chief executive Huh Nam-gu set a cadence of three new clinical programs a year to reach 15 clinical-stage programs by 2030.
- First-half revenue was 28.7 billion won and operating profit 4.6 billion won, the fourth consecutive profitable half since the second half of 2024.
- AMB303, an ADC co-developed with SK Plasma, is the candidate Aimed Bio means to file an IND for this year as it shifts from preclinical deals toward licensing after its own trials.
- In the first half alone the company took positions in three AI biotech firms, Galux, Innocras and Avis, to apply antibody design, biomarker analysis and companion diagnostics across discovery and development.
Compiled by The InvestorSomething wrong?How this is made
Why it matters
- constraint Funding Phase 1 work internally out of a balance sheet this size puts the brain-barrier platform, the AOC programs and the AMB303 trial in competition for the same won, and the three-a-year cadence is the first thing to slip.
- decision Running trials before licensing is a decision to spend cash now for a higher price later, and it converts Aimed Bio from a seller of preclinical assets into a company carrying clinical costs on its own books.
- exposure The receipts that pay for the expansion are triggered by trials Biohaven and Boehringer Ingelheim run, so a partner's timetable, not Aimed Bio's, decides when the money lands.
- contradiction The two write-ups of the same interview word the receipts differently, one as milestone payments and one as licensing payments, leaving it unclear whether upfronts sit inside the 100 billion won total and how much of it recurs.
The company has signed licensing and joint development agreements worth a cumulative 3 trillion won, with Boehringer Ingelheim, Biohaven and others [1]. Cumulative milestone payments actually received will pass 100 billion won this year, chief executive Huh Nam-gu told Seoul Economic Daily [5]. That is about 3.3 percent of the signed total [1]. "We have moved beyond preclinical-stage licensing to become a company that has secured proof of concept (PoC) at the clinical stage," Huh said [20].
His target for the signed column is bigger. "We will secure three clinical programs each year to reach a total of 15 by 2030 and achieve 10 trillion won in technology exports," Huh said [2]. Measured against what is already on the books, that needs roughly 7 trillion won of new agreements. That is about 1.75 trillion won a year across the four years from the September 2026 interview to 2030 [2].
The money on hand is smaller than either figure. Available assets, cash and equivalents plus short-term financial instruments, stood at about 84.2 billion won at the end of the first half [8]. The same half produced a 16 percent operating margin [3]. Split evenly across 15 planned clinical programs, 84.2 billion won is about 5.6 billion won each [4].
Several things now have a claim on it. Huh said the company will "develop and validate a blood-brain barrier (BBB) shuttle platform and then build a drug pipeline based on it" [4], and it signed a joint AOC development agreement with the drug developer Sovargen in March [14]. It also wants to carry trials itself before licensing them out. "You have to prepare on the assumption that you will run the trials yourself, because that is how you get a higher valuation in licensing negotiations," Huh said [12].
Two ways this goes. In the first, partners pay for it: Biohaven confirmed objective responses, with tumors shrinking in patients across multiple cancer types, in a Phase 1 trial of AMB302, an ADC licensed from Aimed Bio [9], and Huh said "the pipeline licensed to Boehringer Ingelheim is also set to begin dosing its first patient soon" [10]. In the second, Aimed Bio absorbs the cost of its own Phase 1 work to lift its asking price, milestone timing slips behind the spending, and three programs a year becomes two. That version needs outside money.
On the evidence, receipts set the pace of the 15-program plan. A reported half in which payments received run at several times first-half revenue would settle it the other way, because at that rate three INDs a year comes out of operating cash rather than the balance sheet.
What to watch
- Whether the AMB303 IND is filed and cleared before year-end, and whether SK Plasma carries any of the trial cost.
- Second-half accounts: a step up in payments received, or a first equity raise against the 84.2 billion won position.
- Biohaven's next move on AMB302 after Phase 1, and whether a Phase 2 start triggers a payment to Aimed Bio.